Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia

Schizophrenia Research

Volumn 162, Issue 1-3, 2015, Pages 57-61

  Strauss, Gregory P ^a   Keller, William R ^b   Koenig, James I ^b   Gold, James M ^b   Ossenfort, Kathryn L ^a   Buchanan, Robert W ^b  

^a BINGHAMTON UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Emotion; Hedonic; Negative symptoms; Olfaction; Oxytocin; Psychosis

Indexed keywords

OXYTOCIN; FRAGRANCE;

ACCURACY; ADULT; ANTISOCIAL BEHAVIOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EMOTIONALITY; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; ODOR RECOGNITION TEST; OLFACTORY DISCRIMINATION; OUTPATIENT; OXYTOCIN BLOOD LEVEL; PRIORITY JOURNAL; SCHIZOPHRENIA; UNIVERSITY OF PENNSYLVANIA SMELL IDENTIFICATION TEST; BLOOD; NEUROPSYCHOLOGICAL TEST; PATTERN RECOGNITION; PHYSICAL STIMULATION; PHYSIOLOGY; PSYCHOLOGICAL INTERVIEW; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SMELLING;

ADULT; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; NEUROPSYCHOLOGICAL TESTS; ODORANTS; OLFACTORY PERCEPTION; OXYTOCIN; PATTERN RECOGNITION, PHYSIOLOGICAL; PHYSICAL STIMULATION; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84923228123     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.12.023     Document Type: Article

References (49)

1. Averbeck B.B., Bobin T., Evans S., Shergill S.S. Emotion recognition and oxytocin in patients with schizophrenia. Psychol. Med. 2012, 42(2):259-266.
2. Beckmann H., Lang R.E., Gattaz W.F. Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 1985, 10(2):187-191.
3. Brewer W.J., Wood S.J., McGorry P.D., Francey S.M., Phillips L.J., Yung A.R., Anderson V., Copolov D.L., Singh B., Velakoulis D., Pantelis C. Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. Am. J. Psychiatry 2003, 160(10):1790-1794.
4. Cohen A.S., Minor K.S. Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophr. Bull. 2010, 36(1):143-150.
5. Cohen A.S., Najolia G.M., Brown L.A., Minor K.S. The state-trait disjunction of anhedonia in schizophrenia: potential affective, cognitive and social-based mechanisms. Clin. Psychol. Rev. 2011, 31(3):440-448.
6. Dantzer R., Tazi A., Bluthe R.M. Cerebral lateralization of olfactory-mediated affective processes in rats. Behav. Brain Res. 1990, 40(1):53-60.
7. Davis M.C., Green M.F., Lee J., Horan W.P., Senturk D., Clarke A.D., Marder S.R. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 2014, 39(9):2070-2077.
8. Davis M.C., Lee J., Horan W.P., Clarke A.D., McGee M.R., Green M.F., Marder S.R. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr. Res. 2013, 147(2-3):393-397.
9. Dickinson C., Keverne E.B. Importance of noradrenergic mechanisms in the olfactory bulbs for the maternal behaviour of mice. Physiol. Behav. 1988, 43:313-316.
10. Dluzen D.E., Muraoka S., Landgraf R. Olfactory bulb norepinephrine depletion abolishes vasopressin and oxytocin preservation of social recognition responses in rats. Neurosci. Lett. 1998, 254(3):161-164.
11. Doty R.L., Shamam P., Dann W. Development of the University of the Pennsylvania Smell Test standardized microen-capsulated test of olfactory function. Physiol. Behav. 1984, 32:489-495.
12. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68(7):678-680.
13. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structural Clinical Interview for DSM-IV Axis I Disorders (SCID-IV). New York State Psychiatric Institute 1997, Biometrics Research, New York.
14. Fischer-Shofty M., Brune M., Ebert A., Shefet D., Levkovitz Y., Shamay-Tsoory S.G. Improving social perception in schizophrenia: the role of oxytocin. Schizophr. Res. 2013, 146(1-3):357-362.
15. Fischer-Shofty M., Shamay-Tsoory S.G., Levkovitz Y. Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls. Front. Neurosci. 2013, 7:127.
16. Gibson C.M., Penn D.L., Smedley K.L., Leserman J., Elliott T., Pedersen C.A. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr. Res. 2014, 156(2-3):261-265.
17. Goldman M., Marlow-O'Connor M., Torres I., Carter C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr. Res. 2008, 98(1-3):247-255.
18. Goldman M.B., Gomes A.M., Carter C.S., Lee R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology 2011, 216(1):101-110.
19. Hawk A.B., Carpenter W.T., Strauss J.S. Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia. Arch. Gen. Psychiatry 1975, 32:343-347.
20. Horta de Macedo L.R., Zuardi A.W., Machado-de-Sousa J.P., Chagas M.H., Hallak J.E. Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task. Psychiatry Res. 2014.
21. Hudry J., Saoud M., D'Amato T., Dalery J., Royet J.P. Ratings of different olfactory judgements in schizophrenia. Chem. Senses 2002, 27(5):407-416.
22. Kamath V., Turetsky B.I., Calkins M.E., Kohler C.G., Conroy C.G., Borgmann-Winter K., Gatto D.E., Gur R.E., Moberg P.J. Olfactory processing in schizophrenia, non-ill first-degree family members, and young people at-risk for psychosis. World J. Biol. Psychiatry 2014, 15(3):209-218.
23. Keri S., Kiss I., Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc. Neurosci. 2009, 4(4):287-293.
24. Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.F., Daniel D., Cienfuegos A., Marder S.R. The Brief Negative Symptom Scale: psychometric properties. Schizophr. Bull. 2011, 37:300-305.
25. Kring A.M., Moran E.K. Emotional response deficits in schizophrenia: insights from affective science. Schizophr. Bull. 2008, 34(5):819-834.
26. Lee M.R., Wehring H.J., McMahon R.P., Linthicum J., Cascella N., Liu F., Bellack A., Buchanan R.W., Strauss G.P., Contoreggi C., Kelly D.L. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr. Res. 2013, 145(1-3):110-115.
27. Llerena K., Strauss G.P., Cohen A.S. Looking at the other side of the coin: a meta-analysis of self-reported emotional arousal in people with schizophrenia. Schizophr. Res. 2012, 142(1-3):65-70.
28. Malaspina D., Coleman E. Olfaction and social drive in schizophrenia. Arch. Gen. Psychiatry 2003, 60(6):578-584.
29. Malaspina D., Coleman E., Goetz R.R., Harkavy-Friedman J., Corcoran C., Amador X., Yale S., Gorman J.M. Odor identification, eye tracking and deficit syndrome schizophrenia. Biol. Psychiatry 2002, 51(10):809-815.
30. Moberg P.J., Arnold S.E., Doty R.L., Kohler C., Kanes S., Seigel S., Gur R.E., Turetsky B.I. Impairment of odor hedonics in men with schizophrenia. Am. J. Psychiatry 2003, 160(10):1784-1789.
31. Moberg P.J., Kamath V., Marchetto D.M., Calkins M.E., Doty R.L., Hahn C.G., Borgmann-Winter K.E., Kohler C.G., Gur R.E., Turetsky B.I. Meta-analysis of olfactory function in schizophrenia, first-degree family members, and youths at-risk for psychosis. Schizophr. Bull. 2014, 40(1):50-59.
32. Overall J.E., Gorman D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10:799-812.
33. Pedersen C.A., Gibson C.M., Rau S.W., Salimi K., Smedley K.L., Casey R.L., Leserman J., Jarskog L.F., Penn D.L. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr. Res. 2011, 132(1):50-53.
34. Pfohl B.M., Blum N., Zimmerman M. Structured Interview for DSM-IV Personality 1997, American Psychiatric Publishing, Inc. 1st ed.
35. Rubin L.H., Carter C.S., Bishop J.R., Pournajafi-Nazarloo H., Drogos L.L., Hill S.K., Ruocco A.C., Keedy S.K., Reilly J.L., Keshavan M.S., Pearlson G.D., Tamminga C.A., Gershon E.S., Sweeney J.A. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr. Bull. 2014.
36. Rubin L.H., Carter C.S., Bishop J.R., Pournajafi-Nazarloo H., Harris M.S., Hill S.K., Reilly J.L., Sweeney J.A. Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. Schizophr. Res. 2013, 146(1-3):138-143.
37. Rubin L.H., Carter C.S., Drogos L., Jamadar R., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia. Schizophr. Res. 2011, 130(1-3):266-270.
38. Rubin L.H., Carter C.S., Drogos L., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 2010, 124(1-3):13-21.
39. Strauss G.P., Allen D.N., Ross S.A., Duke L.A., Schwartz J. Olfactory hedonic judgment in patients with deficit syndrome schizophrenia. Schizophr. Bull. 2010, 36(4):860-868.
40. Strauss G.P., Gold J.M. A new perspective on anhedonia in schizophrenia. Am. J. Psychiatry 2012, 169(4):364-373.
41. Strauss G.P., Hong L.E., Gold J.M., Buchanan R.W., McMahon R.P., Keller W.R., Fischer B.A., Catalano L.T., Culbreth A.J., Carpenter W.T., Kirkpatrick B. Factor structure of the Brief Negative Symptom Scale. Schizophr. Res. 2012, 142(1-3):96-98.
42. Strauss G.P., Keller W.R., Buchanan R.W., Gold J.M., Fischer B.A., McMahon R.P., Catalano L.T., Culbreth A.J., Carpenter W.T., Kirkpatrick B. Next-Generation Negative Symptom Assessment for Clinical Trials: Validation of the Brief Negative Symptom Scale. Schizophr Res. 2012, 142:88-92.
43. Strauss G.P., Kappenman E.S., Culbreth A.J., Catalano L.T., Lee B.G., Gold J.M. Emotion regulation abnormalities in schizophrenia: cognitive change strategies fail to decrease the neural response to unpleasant stimuli. Schizophr. Bull. 2013, 39(4):872-883.
44. Tremeau F., Antonius D., Cacioppo J.T., Ziwich R., Jalbrzikowski M., Saccente E., Silipo G., Butler P., Javitt D. In support of Bleuler: objective evidence for increased affective ambivalence in schizophrenia based upon evocative testing. Schizophr. Res. 2009, 107(2-3):223-231.
45. Wacker D.W., Ludwig M. Vasopressin, oxytocin, and social odor recognition. Horm. Behav. 2012, 61(3):259-265.
46. Walss-Bass C., Fernandes J.M., Roberts D.L., Service H., Velligan D. Differential correlations between plasma oxytocin and social cognitive capacity and bias in schizophrenia. Schizophr. Res. 2013, 147(2-3):387-392.
47. Woodberry K.A., Seidman L.J., Giuliano A.J., Verdi M.B., Cook W.L., McFarlane W.R. Neuropsychological profiles in individuals at clinical high risk for psychosis: relationship to psychosis and intelligence. Schizophr. Res. 2010, 123(2-3):188-198.
48. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
49. Woolley J.D., Chuang B., Lam O., Lai W., O'Donovan A., Rankin K.P., Mathalon D.H., Vinogradov S. Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology 2014, 47:116-125.